ACPU
SUPN icon

Arrowgrass Capital Partners (US)’s Supernus Pharmaceuticals SUPN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-136,951
Closed -$4.53M – 290
2019
Q2 		$4.53M Buy
+136,951
New +$4.69M 0.11% 202
2018
Q2 		– Sell
-98,600
Closed -$4.52M – 225
2018
Q1 		$4.52M Buy
+98,600
New +$4.11M 0.15% 78

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s SUPN Position: Q3 2019 in Review

Arrowgrass Capital Partners (US) sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 136,951 shares — an estimated $4.53M sold.

Arrowgrass Capital Partners (US) first reported a position in SUPN in Q1 2018 and held it in 2 quarters. The position peaked at $4.53M in Q2 2019. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

  • Arrowgrass Capital Partners (US) reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 136,951 Supernus Pharmaceuticals shares in Q3 2019, an estimated $4.53M.
  • Arrowgrass Capital Partners (US) first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Arrowgrass Capital Partners (US)'s Supernus Pharmaceuticals position peaked at $4.53M in Q2 2019.
  • 243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2019, filed 14 Nov 2019.